Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Takeda Pharmaceutical said on August 22 that its tyrosine kinase inhibitor Cabometyx (cabozantinib) paired with the PD-L1 inhibitor Tecentriq (atezolizumab) showed a statistically significant extension in progression-free survival (PFS) in a pivotal trial for metastatic castration-resistant prostate cancer. PFS was…
To read the full story
Related Article
- Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
January 29, 2024
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





